Related Experiment Video
Updated: Jul 3, 2026
04:56
Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
Published on: August 4, 2023
Chemotherapy-induced thrombosis: a role for microparticles and tissue factor?
Daniel Lechner1, Ansgar Weltermann
1Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Seminars in Thrombosis and Hemostasis
|July 23, 2008
Summary
Chemotherapy increases the risk of blood clots in cancer patients. This review explores how tissue factor and microparticles contribute to chemotherapy-induced hypercoagulability and thrombosis.
Area of Science:
- Oncology
- Hematology
- Biochemistry
Background:
- Chemotherapy is a known risk factor for thromboembolic events in cancer patients.
- The precise mechanisms underlying chemotherapy-induced thrombosis are not fully understood.
- Emerging evidence links prothrombotic states in cancer to circulating tissue factor-exposing microparticles.
Purpose of the Study:
- To review the roles of tissue factor and microparticles in chemotherapy-induced hypercoagulability.
- To synthesize current understanding of the pathogenetic mechanisms involved.
- To highlight the clinical relevance of these factors in cancer-associated thrombosis.
Main Methods:
- Literature review of relevant studies.
- Analysis of existing clinical trial data.
- Synthesis of pathogenetic mechanisms linking chemotherapy, tissue factor, microparticles, and thrombosis.
Main Results:
- Chemotherapy can induce a prothrombotic state in cancer patients.
- Circulating tissue factor-exposing microparticles are increasingly implicated in this process.
- These microparticles may play a significant role in the development of thrombosis.
Conclusions:
- Tissue factor and microparticles are critical components in understanding chemotherapy-induced hypercoagulability.
- Further clinical investigation is warranted to elucidate their individual contributions to thrombosis risk.
- Targeting these pathways may offer novel strategies for preventing thromboembolic events in cancer patients.
More Related Videos
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
09:26Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
Published on: February 20, 2015
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...